OR WAIT null SECS
October 04, 2021
Manufacturing facility to provide 1.5 million square feet of bioproduction technologies
September 27, 2021
Recent FDA actions may finally usher in access boost to follow-on biologics in the US
September 24, 2021
R&D partnership with VaxEquity outlines plan to use saRNA as a go-to therapeutic
September 23, 2021
The steps pharma manufacturers can take to mitigate transportation costs amid Covid’s supply-chain crunch
September 22, 2021
Financial commitment expected to expand the development and commercialization pipeline for new medicines
September 16, 2021
Deal is dependent on FDA approval of Phathom’s vonoprazan compound
September 15, 2021
Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot
September 14, 2021
Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions
September 13, 2021
Latest construction plan continues CDMO’s vision for biopharma expansion
September 09, 2021
CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand